JP2024522820A - ２－アリールベンゾイミダゾールの治療上有効な経口投与 - Google Patents

２－アリールベンゾイミダゾールの治療上有効な経口投与 Download PDF

Info

Publication number
JP2024522820A
JP2024522820A JP2023578189A JP2023578189A JP2024522820A JP 2024522820 A JP2024522820 A JP 2024522820A JP 2023578189 A JP2023578189 A JP 2023578189A JP 2023578189 A JP2023578189 A JP 2023578189A JP 2024522820 A JP2024522820 A JP 2024522820A
Authority
JP
Japan
Prior art keywords
tqs
administered
salt
dose
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023578189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522820A5 (enExample
Inventor
ジョナス オガーラ ハンネスタッド，
スティーブン オーガスト スミス，
サンジャイ クマール カッカー，
Original Assignee
トランクイス セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トランクイス セラピューティクス， インコーポレイテッド filed Critical トランクイス セラピューティクス， インコーポレイテッド
Publication of JP2024522820A publication Critical patent/JP2024522820A/ja
Publication of JP2024522820A5 publication Critical patent/JP2024522820A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023578189A 2021-06-17 2022-06-17 ２－アリールベンゾイミダゾールの治療上有効な経口投与 Pending JP2024522820A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163211636P 2021-06-17 2021-06-17
US63/211,636 2021-06-17
US202263300551P 2022-01-18 2022-01-18
US63/300,551 2022-01-18
PCT/US2022/034012 WO2022266455A1 (en) 2021-06-17 2022-06-17 Therapeutically effective oral administration of a 2 arylbenzimidazole

Publications (2)

Publication Number Publication Date
JP2024522820A true JP2024522820A (ja) 2024-06-21
JP2024522820A5 JP2024522820A5 (enExample) 2025-06-25

Family

ID=84527631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023578189A Pending JP2024522820A (ja) 2021-06-17 2022-06-17 ２－アリールベンゾイミダゾールの治療上有効な経口投与

Country Status (4)

Country Link
US (2) US20240307356A1 (enExample)
EP (1) EP4355326A4 (enExample)
JP (1) JP2024522820A (enExample)
WO (1) WO2022266455A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202416960A (zh) * 2022-06-17 2024-05-01 美商特朗奎斯治療股份有限公司 2-芳基苯并咪唑化合物之調配物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3000985C (en) * 2014-10-14 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Method for treating neurodegenerative diseases
AU2016371598B2 (en) * 2015-12-15 2021-05-13 The Board Of Trustees Of The Leland Stanford Junior University Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
US20240316008A1 (en) * 2020-06-22 2024-09-26 Tranquis Therapeutics, Inc. Treatment of systemic immune activation syndromes

Also Published As

Publication number Publication date
WO2022266455A1 (en) 2022-12-22
EP4355326A4 (en) 2025-04-23
US20250281462A1 (en) 2025-09-11
EP4355326A1 (en) 2024-04-24
US20240307356A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
DE60028754T2 (de) Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
EP3984528B1 (en) Pharmaceutical compositions comprising nilotinib
DE69426984T2 (de) Arzneizubereitung
US7022345B2 (en) Oral solid pharmaceutical formulations with pH-dependent multiphasic release
ES2596291T3 (es) Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
EP2694037B1 (en) Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
JP2000515555A (ja) 医薬組成物
EP3785698B1 (en) Edaravone pharmaceutical composition
JP7578585B2 (ja) 骨髄線維症の血小板数非依存的処置方法
BR112014011981B1 (pt) FORMULAgOES FARMACEUTICAS SOLIDAS ORAIS, SEUS PROCESSOS DE PREPARAgAO E USOS
US20240374516A1 (en) Ready to use oral pharmaceutical suspension of dasatinib
BRPI0812432B1 (pt) Extrusados, seu uso, e medicamento
US20120141586A1 (en) Thrombin receptor antagonist and clopidogrel fixed dose tablet
US20250281462A1 (en) Therapeutically effective oral administration of a 2 arylbenzimidazole
CA2985379A1 (en) Micronized pharmaceutical compositions for treatment of angiogenisis conditions
EP3993809B1 (en) System for enhancing therapeutic compliance of the anti-cancer compound e7766
EP3386516A1 (en) Pharmaceutical formulations for treating skin disorders and methods for fabricating and using thereof
JP2021512140A (ja) 肝細胞癌の治療のための併用療法
CN117794531A (zh) 2-芳基苯并咪唑的治疗上有效的口服给药
EP3700531B1 (en) Dosage regimen of paliperidone palmitate extended-release injectable suspension
CN106176616B (zh) 兽用水溶性乙氧酰胺苯甲酯纳米粉、制备方法及应用
WO2020048449A1 (zh) 包含1,3,5-三嗪衍生物或其盐的固体药物组合物
CN103845333A (zh) 阿伐那非新用途
US6645961B1 (en) Dry granulation formulation for an HIV protease inhibitor
KR20190064208A (ko) 피마살탄을 포함하는 고체 분산체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250617

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260128